MenQuadfi Gains EU Infant Approval, Entering an Interchangeable Market Against an Entrenched Peer

EU Approves Sanofi's MenQuadfi for Infants from Six Weeks

Sanofi announced that the European Commission (EC) has approved an expanded indication for its MenQuadfi vaccine, allowing its use in infants from six weeks of age in the EU. This approval extends protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Previously, MenQuadfi was approved for individuals aged 12 months and older. The decision, supported by a positive opinion from the Committee for Medicinal Products for Human Use on June 25, 2026, addresses the high risk and severe complications of meningococcal disease in infants, providing healthcare providers with a crucial option for early immunization within routine schedules.

• The European Commission's approval of MenQuadfi for infants from six weeks significantly broadens its utility, enabling early protection against life-threatening invasive meningococcal disease caused by serogroups A, C, W, and Y. This expansion is crucial for public health, as infants face the highest risk of mortality and severe long-term complications. It offers healthcare providers flexibility to integrate the vaccine into routine immunization schedules, aiming to increase vaccine coverage among the most vulnerable population.
• The expanded indication is underpinned by comprehensive data from the pivotal MET58 clinical study. This study rigorously evaluated MenQuadfi's immunogenicity, safety, and tolerability in infants starting from six weeks of age. The robust immunogenicity data established across a broad age range, from six weeks through adulthood, supports the vaccine's efficacy and safety profile, which was found to be comparable to other licensed MenACWY vaccines.
• MenQuadfi's approval includes flexible dosing regimens tailored for infants. A standard 2+1 schedule involves two primary doses at least two months apart, followed by a booster in the second year of life. For infants at increased risk of serogroup A exposure, a 3+1 schedule is available. The vaccine can also be safely co-administered with other routine infant vaccines, including DTaP-IPV-HepB-Hib, rotavirus vaccine, and 10-valent pneumococcal conjugate vaccine (PCV10), simplifying vaccination schedules.

The Burden of IMD: Why Infants Need Early Protection

Invasive meningococcal disease (IMD) exhibits a distinct age-related incidence pattern, with infants consistently identified as the most vulnerable population. Globally, the highest rates of disease are observed in infants, followed by secondary peaks in young children, adolescents, and, in some countries, older adults. Data from the Netherlands (2017-2019) illustrates this, showing the highest incidence in children aged 0-4 years at 4 cases per 100,000 inhabitants. Similarly, studies from Israel (1990-1994) found that infants under one year accounted for the highest proportion of isolates (34.8%), followed by children aged 1 to 5 years (25.8%). This bimodal age distribution is further supported by Australian data, which identified a primary peak in children four years or younger and a secondary peak in adolescents and young adults.

The epidemiology of IMD is also characterized by significant geographic and temporal shifts in the prevalence of causative serogroups. Serogroup A has been historically dominant in major European epidemics and remains a significant cause of morbidity and mortality in the African meningitis belt and parts of Asia. In contrast, serogroup C has been particularly associated with disease in adolescents and young adults and has been linked to severe outcomes, including fulminant meningococcemia. More recently, from 2010 to 2019, a notable global increase in IMD caused by serogroups W and Y has been observed. Serogroup W has been associated with outbreaks in South America and predominates in individuals aged 45 and older in regions like the Netherlands, while serogroup Y shows increased incidence among the elderly, as well as infants and adolescents. Despite advances in medicine, IMD continues to have a high mortality rate of 5-10%.

MenQuadfi's Expanded Role in the Evolving IMD Landscape

The prevention and management landscape for invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y has evolved substantially over the past five years, driven predominantly by advances in vaccine development rather than novel treatment regimens. Quadrivalent conjugate vaccines such as MenACWY-TT have demonstrated non-inferiority to established comparators (Menveo, Menactra, MCV4-DT, Menomune-A/C/Y/W-135) across pediatric, adolescent, adult, and older-adult populations, with favorable seroresponse and seroprotection profiles and no meaningful safety differences. Building on this foundation, next-generation pentavalent formulations have emerged: NmCV-5 (targeting A, C, Y, W, and X) showed non-inferior immunogenicity to licensed MenACWY-TT in a Mali-based phase 3 trial enrolling 1,325 infants and toddlers, with seroprotection differences within acceptable margins at both 9- and 15-month dosing timepoints and no vaccine-related serious adverse events. Similarly, combined MenABCWY vaccines—including Pfizer's Penbraya (licensed in 2023) and GSK's Penmenvy (FDA-licensed February 2025)—have advanced clinical and regulatory milestones, with ACIP endorsing Penmenvy in April 2025 for co-administration scenarios in individuals aged 10–23 years, reflecting a strategic shift toward simplifying immunization schedules by consolidating serogroup B and ACWY coverage into single-product regimens.

Despite these prevention-focused advances, real-world breakthrough case data and emerging antimicrobial resistance signal persistent clinical challenges. A U.S. surveillance analysis (2014–2018) of 822 reported ACWY cases found that 4% occurred in previously vaccinated individuals, with waning immunity (50% of breakthrough cases occurring >3 years post-vaccination), incomplete vaccination status, and underlying immunosuppression (including HIV infection and eculizumab therapy) identified as key contributing factors; notably, case fatality did not differ between vaccinated and unvaccinated patients, underscoring that current vaccines do not fully eliminate mortality risk even when partially effective. More concerning from a therapeutic standpoint is the 2023–2025 emergence in China of a dual-resistant MenY clonal complex (cc23, ST-18108) exhibiting resistance to both cefotaxime (MIC 0.75–1 μg/mL) and ciprofloxacin (MIC 0.125 μg/mL), alongside intermediate penicillin susceptibility—though isolates remained susceptible to ceftriaxone. Whole-genome sequencing linked this resistance to specific PBP2 mutations (A311V, I312M, V316P, T483S, N512Y, G545S) and a GyrA T91I mutation, raising concerns about the durability of standard empiric treatment and chemoprophylaxis protocols should this clone achieve broader geographic spread.

Taken together, the past five years reflect an immunization-centric evolution of the IMD landscape—marked by pentavalent vaccine innovation, expanding combination products, and refined immunogenicity benchmarking—rather than fundamental shifts in acute treatment protocols. No published trial data during this period specifically addressed changes in antibiotic regimens, treatment duration, or novel therapeutics for active IMD caused by these serogroups. This creates a notable evidence gap precisely as resistance signals emerge, reinforcing the strategic importance of vaccines like MenQuadfi in reducing disease incidence upstream, while highlighting the need for continued resistance surveillance and, potentially, renewed investment in treatment-focused trial data to complement prevention strategies.

MET58 Study: Immunogenicity and Safety Data for Infants

A pivotal Phase 3, non-inferiority trial (NCT05093829) was conducted to evaluate the immunogenicity and safety of the novel pentavalent meningococcal vaccine, NmCV-5. The study enrolled infants in Mali and compared the response of NmCV-5 against a licensed quadrivalent conjugate vaccine, MenACWY-TT, when co-administered with routine childhood immunizations.